horizon pharma stock price
ae7ba6ffffed0f96c1bd013322660b5b
NASDAQ:HZNP - Horizon Pharma Stock Price, Price Target & More Where will Horizon Pharma's stock price be in 2018? 11 equities research analysts have issued 12-month price targets for Horizon Pharma's stock. Their predictions range from $13.00 to $30.00. On average, they expect Horizon Pharma's share price to reach $19.18 in the next twelve months. View Analyst Ratings for Horizon Pharma.
90ee34256148c47e89bae6259e334529
Acceleron Pharma Inc.  (XLRN) Kite Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares. Kite Pharma, Inc. (Nasdaq:KITE) today announced the closing of its previously announced underwritten public offering of 4,750,000 shares of its common stock at a price to the public of $75.
75a2269f58b4d403ed41f8fb7fca77dd
- HZN: Get the latest Horizon Global stock price and detailed information including HZN news, historical charts and realtime prices. HZN: Get the latest Horizon Global stock price and detailed information including HZN news, historical charts and realtime prices.
03881e26560bd8a69ad1fa99701424ce
- $ 27.26. 52 Week High/Low 52 Week High is the highest sales price the stock has achieved during the regular trading hours during the most recent 52 week period. 52 Week Low is the lowest sales price the stock has fallen to during the regular trading hours during the most recent 52 week period. $ 29.87 / $ 9.35.
73aa1276ae536c88ad256735b218f1d1
ARRY Stock: Price Target in View for Array BioPharma Inc Looking at some recent stock price activity for Array BioPharma Inc. (NASDAQ:ARRY), we have spotted shares trading near the $10.92 level. Looking at some popular historical levels, we note that the 52-week high is presently $12.56, and the 52-week low is currently $6.96.
de747fe01dcfffc0ae54e3656d5e35e8
- Where will Tenax Therapeutics' stock price be in 2018? 1 brokerages have issued 12-month price objectives for Tenax Therapeutics' stock. Their forecasts range from $2.50 to $2.50. On average, they expect Tenax Therapeutics' stock price to reach $2.50 in the next year. View Analyst Ratings for Tenax Therapeutics. Who are some of Tenax Therapeutics' key competitors?
7fe0e7ef993d36891d2cbb3cead433f7
- Industry, Sector and Symbol: 1  Sector: Medical. 2  Industry: Pharmaceuticals - NEC. 3  Sub-Industry: Pharmaceuticals. 4  Symbol: NASDAQ:HZNP. 5  CUSIP: 44047T10. 6  Web: www.horizonpharma.com.
49b37942a3b888c7fd56dc4c2c2d2a27
Teva Pharmaceutical Industries Limitedâs (TEVA) Hold Rating Reiterated at Mizuho Mizuho reiterated their hold rating on shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) in a report issued on Monday morning. They currently have a $15.00 price objective on the stock. Other research analysts have also recently issued reports about the company.
f62c4c7696d500bfa45395652afa8410
- 6 brokerages have issued twelve-month price objectives for Arbutus Biopharma Corp's shares. Their forecasts range from $5.00 to $10.00. On average, they anticipate Arbutus Biopharma Corp's stock price to reach $7.00 in the next year.
14c3e93e3c1e131849a90a802859a7cc
NASDAQ:ARRY - Array Biopharma Stock Price, Price Target & More 8 analysts have issued 12-month price objectives for Array BioPharma's stock. Their forecasts range from $11.00 to $18.00. On average, they expect Array BioPharma's stock price to reach $14.63 in the next year. View Analyst Ratings for Array BioPharma.
6debf9b66c7de046c4394b7f5cc616cd
NYSE:NKE - Nike Stock Price, Price Target & More Where will Proofpoint's stock price be in 2018? 25 brokerages have issued 1-year price targets for Proofpoint's shares. Their forecasts range from $69.00 to $124.00. On average, they anticipate Proofpoint's stock price to reach $107.87 in the next twelve months. View Analyst Ratings for Proofpoint. What are Wall Street analysts saying about Proofpoint stock?
6bb3a7e710ff4fc69562cc69be427e0e
The Earliest Writing Machines A writing machine was patented in England in 1714, a music typewriter was invented c. 1747, and a machine that enabled a blind person to write letters to a sighted person was made in 1808.
afde62e50fd25773b7be0171003714fa
WellPoint Inc. (WLP) Ex-Dividend Date Scheduled for December 03, 2014 WellPoint Inc. ( WLP ) will begin trading ex-dividend on December 03, 2014. A cash dividend payment of $0.4375 per share is scheduled to be paid on December 22, 2014. Shareholders who purchased WLP stock prior to the ex-dividend date are eligible for the cash dividend payment. This marks the 4th quarter that WLP has paid the same dividend. At the current stock price of $127.77, the dividend yield is 1.37%.
39502df46f1569dd1c1c0ca12a945626
Roth Capital Boosts Price Target for Kite Pharma Inc (KITE) on the Back of Positive Six Month ZUMA-1 Data Roth Capital Boosts Price Target for Kite Pharma Inc (KITE) on the Back of Positive Six Month ZUMA-1 Data. Kite Pharma Inc (NASDAQ:KITE) shares are on the run, after the drug maker announced the much-awaited top line results from its Phase 2 ZUMA-1 trial of KTE-C19 in patients with r/r DLBCL, which were an overwhelming success.
dcee4866a4a1838f9e4364f3a2709f0d
NASDAQ:NYMT - New York Mortgage Trust Stock Price, Price Target & More 5 brokerages have issued 12-month target prices for New York Mortgage Trust's stock. Their forecasts range from $6.00 to $6.50. On average, they anticipate New York Mortgage Trust's share price to reach $6.19 in the next twelve months. View Analyst Ratings for New York Mortgage Trust.
610ba805d1dd4785f0d571cce5928e35
- One More Thing About That Fancy New Fox News Deck. Veeva Systems, an enterprise cloud provider for life sciences companies like Pfizer, IPO’d on the NYSE this morning, raising around $217 million by upping its share price $20. Veeva saw a pop of 83.5% in initial trading after starting at a value over $2.4 billion. Veeva closed at $37.16, up 85.8%.
16c8c1dcf1e1ae0f3802f67622ad4659
Lawson stock price shoots past Infor's bid Lawson stock price shoots past Infor's bid. Wall Street awaits a bid for the St. Paul company above the current $1.8 billion offer. Shares of Lawson Software rose nearly 6 percent Monday, and stayed well above last week's takeover bid price of $11.25 per share in cash, an indication that some shareholders anticipate a bid higher than the current $1.8 billion.
f95ae8f3cffb3a0bdc6f3a1f34369132
- Analyst Amit Daryanani's new price target was 12% above the stock's closing price of $138.99 on Wednesday, and 6.4% above the average target of the 42 analysts surveyed by FactSet of $145.69. Daryanani outlook for its services business implies it will be a $48 billion to $50 billion business by fiscal 2020.
05fa445aca4e569514514c16c1022269
- 5 analysts have issued 12-month target prices for Progenics Pharmaceuticals' shares. Their predictions range from $11.00 to $14.00. On average, they expect Progenics Pharmaceuticals' stock price to reach $12.20 in the next year.
ea22f7b2c81fc72c4597b8ed79497769
- A SIGNIFICANT DISTRIBUTEE. On June 24, 2013, Pfizer Inc. (“Pfizer”) accepted 405,117,195 shares of Pfizer common stock validly. tendered in exchange for 400,985,000 shares of common stock of Zoetis Inc. (“Zoetis”), representing all. of the Zoetis stock then owned by Pfizer (the “Exchange”). Pursuant to the Exchange, tendering Pfizer. shareholders received 0.9898 of a share of Zoetis common stock in exchange for each share of Pfizer. common stock validly tendered and accepted by Pfizer.
27b1876b4c8c3d942884b1a1e9bbca54
- Tetraphase Pharmaceuticals stock price target cut to $12 from $54 at SunTrust Robinson Humphrey. 7:10 a.m. Sept. 9, 2015 - Tomi Kilgore
0d11bdbbc431f8525e08f46c51a3000c
Zoetis Records show that Pfizer officially filed for registration of a Class A stock with the U.S. Securities and Exchange Commission on 10 August 2012. Zoetis' IPO on 1 February 2013 sold 86.1 million shares for US$ 2.2 billion. Shares sharply rose 19% by the end of the trading day to $35.01 a share, up from $26.
02ad658c54c509598f3f73ff903ebd79
- Amphastar Pharmaceuticals Reaches Analyst Target Price. In recent trading, shares of Amphastar Pharmaceuticals Inc have crossed above the average analyst 12-month target price of $21.00, changing hands for $21.26/share.
25e7a9bc61df8ded0e10bed79cf078fb
NYSE:CARS - Cars.com Stock Price, Price Target & More 13 equities research analysts have issued 1 year price targets for Cypress Semiconductor's stock. Their predictions range from $11.00 to $18.00. On average, they expect Cypress Semiconductor's share price to reach $14.85 in the next twelve months.
d2dd16deaccf060c7325af149816cc80
- 3 brokers have issued 1 year target prices for NBT Bancorp's stock. Their forecasts range from $28.00 to $33.50. On average, they expect NBT Bancorp's share price to reach $30.83 in the next year.
0994cf58596fcd09c6f092ce7f1bf914
- Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of an Additional Notice of Allowance ... GlobeNewswire (press release) - 4 hours ago. RAYOS, known as LODOTRA® in Europe, is a proprietary delayed-release formulation of low-dose prednisone.